Home > News & Media > News
Communication starts here.
2016.10
Par Pharmaceutical, Inc filed its notice of appeal for the distribution of injunction bonds in generic Megace ES patent suit
2016.09
TWi Pharmaceuticals Awarded US$12.7 Million In Generic MEGACE ES® Patent Suit
2016.09
TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Androgel 1.62%
2015.09
TWi Pharmaceuticals Issues GDR and raised NT$ 2.83 Billion
2015.09
TWi Pharmaceuticals President & CEO Ms. Tina Guilder will resign from her current roles and Chairman Dr. Chih-Ming Chen will become interim President & CEO
2015.08
TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69
2015.08
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia
2015.07
TWi Pharmaceuticals Launches Generic MEGACE ES® After Favorable Decision In Patent Suit
2015.06
TWi Pharmaceuticals Receives US FDA Final Approval on Generic Guanfacine HCl ER Tablet
2015.05
TWi Pharmaceuticals Announced the promotion of R&D EVP Jianbo Xie as COO

 

Pages:1 - 2 - 3 - 4 - 5 - 6« Pre · Next »